Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281398 | 1.00 | NR4A2 (0.59) | NR4A2KMT2ANR1H4AKR1C3NPC1 | |
| SCHEMBL18952331 | 0.85 | PARP1 (0.56) | — | |
| SCHEMBL9741522 | 0.85 | NR4A2 (0.61) | NR4A2KMT2ANR1H4AKR1C3NPC1 | |
| SCHEMBL3239165 | 0.84 | KMT2A (0.65) | NR4A2KMT2ANR1H4AKR1C3NPC1 | |
| SCHEMBL931583 | 0.83 | NR1H4 (0.75) | NR4A2KMT2ANR1H4AKR1C3NPC1 | |
| SCHEMBL8417231 | 0.83 | KMT2A (0.63) | NR4A2KMT2ANR1H4AKR1C3NR4A1 | |
| SCHEMBL17416724 | 0.83 | TDP1 (0.41) | NR4A2KMT2ANR1H4MRGPRX4 | |
| SCHEMBL28028400 | 0.83 | MRGPRX4 (0.56) | NR1H4NPC1RAB9AMRGPRX4CYSLTR1 | |
| SCHEMBL5009881 | 0.81 | NR4A2 (0.65) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL9803295 | 0.80 | KMT2A (0.80) | NR4A2KMT2ANR1H4AKR1C3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| EP-1635835-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110452-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | NR4A2 999/4885KMT2A 824/4885NR1H4 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.